Profluentbio Partners with GEMMABio on AI for Liver Diseases
Summary
Profluentbio is collaborating with GEMMABio, supported by an ARPA-H award, to develop AI-designed base editors for two rare and severe liver diseases. This partnership exemplifies the application of advanced AI in biology for patient-focused medicine.
Why it matters
This demonstrates a concrete application of advanced AI in drug discovery and genetic therapy, highlighting how AI can accelerate solutions for complex medical challenges and create new market opportunities.
How to implement this in your domain
- 1Explore potential AI applications within your own R&D pipeline for drug discovery or therapy development.
- 2Investigate partnership opportunities with AI-first biotech companies.
- 3Allocate resources to research and develop AI-driven genetic editing tools.
- 4Monitor ARPA-H funding initiatives for future collaboration or grant opportunities.
Who benefits
Key takeaways
- AI is being used to develop advanced genetic therapies for rare diseases.
- Profluentbio and GEMMABio are collaborating with ARPA-H support.
- This partnership focuses on AI-designed base editors for liver diseases.
- It showcases AI's potential to accelerate medical innovation.
Original post by @nathanbenaich
"news! @profluentbio is partnering with GEMMABio under an @ARPA_H award to develop AI-designed base editors for two devastating rare liver diseases. another powerful example of frontier AI for biology moving towards medicines for patients."
View on XOriginally posted by @nathanbenaich on X · view source
Want to go deeper?
Turn these trends into skills with Learnijoy's hands-on AI & tech courses.
Explore coursesMore in AI Research
Anthropic Uncovers Hidden Conceptual Space Within Claude AI
Anthropic researchers have developed a new technique, the Jacobian lens, to gain unprecedented insight into the internal workings of large language models like Claude. This tool reveals how the AI processes information and forms concepts, offering a clearer understanding of its reasoning.
OpenAI's GPT-5.6 Prioritizes Cost Efficiency and Token Optimization
OpenAI has launched GPT-5.6, a new model that focuses on cost-effectiveness and token efficiency rather than just benchmark scores, outperforming Fable 5 in coding agent tasks with significantly lower resource usage. The model achieves this through adaptive reasoning, parallel agents, programmatic tool use, and higher token efficiency.
Meta Launches Muse Spark 1.1, a Production Stack for AI Agents
Meta has released Muse Spark 1.1, an AI agent system that integrates a 1M-token context window, parallel sub-agents, computer use, tool orchestration, and context compaction, available via a new OpenAI-compatible API in public preview. This aims to provide a comprehensive infrastructure for building long-running, production-grade AI agents.